ReDream Brands launched in August 2026 as a direct-to-consumer sleep health platform uniting four industry names—cpap.com, The CPAP Shop, Lofta, and sleeping.com—to target the cash-pay obstructive sleep apnea market across North America. Backed by Cathay Capital, the platform seeks to address widespread underdiagnosis of the chronic condition.
Obstructive sleep apnea remains one of the most widespread yet underdiagnosed chronic medical conditions in the United States. An estimated 40 million Americans suffer from obstructive sleep apnea (OSA). Clinical data indicates that approximately 80% of these adults remain undiagnosed and untreated. To service this patient demographic, Cathay Capital orchestrated the creation of ReDream Brands through strategic transactions involving a joint venture with AdaptHealth and the subsequent acquisition of Lofta, alongside a credit facility led by Twin Brook Capital Partners.
In Plain English: The Clinical Takeaway
- Integrated Care Scale: Combining four distinct entities allows the new business to ship over 700,000 annual customer orders while standardizing digital engagement and clinical education.
Market Dynamics and Brand Ecosystem
The newly formed platform operates as a single, integrated business while maintaining distinct consumer-facing brands tailored to specific stages of the patient journey. According to announcements released by Cathay Capital in August 2026, cpap.com functions as the largest full-service retailer for the direct-pay OSA market. Meanwhile, The CPAP Shop operates as a market leader in value and convenience, and Lofta serves as an industry leader in home sleep testing and coaching.
Rounding out the portfolio, sleeping.com acts as a private-label provider of CPAP supplies and related products. Joe Megibow, Chief Executive Officer of ReDream Brands, emphasized the clinical necessity of this consolidation, stating, “Millions of people struggle with health-impacting sleep disorders that too often go undiagnosed or untreated.” Mark Woods, Partner at Cathay Capital, noted that the platform represents an important step in serving tens of millions of OSA sufferers by focusing on sleep health at scale.
| Brand Name | Primary Clinical Function | Market Role |
|---|---|---|
| cpap.com | Full-service equipment retail | Largest direct-pay retailer in North America |
| The CPAP Shop | Supplies, value, and convenience | Value and accessibility leader |
| Lofta | Home sleep testing and coaching | Diagnostic and initial recovery gateway |
| sleeping.com | Private-label supply distribution | Proprietary product provider |
Epidemiological Impact and Public Health Imperative
The diagnosed sleep apnea market currently stands at an estimated $8 billion, yet this figure reflects only a fraction of the category’s full economic and clinical opportunity. Because four out of five OSA sufferers are never formally evaluated by a physician, healthcare systems face a hidden burden. By streamlining access through home diagnostics and national fulfillment from three regional warehouses across the East, Central, and Western United States, ReDream Brands attempts to bridge the gap between screening and chronic disease management.
Contraindications & When to Consult a Doctor
Conclusion and Future Outlook
The launch of ReDream Brands marks a shift in how cash-pay sleep medicine is delivered across North America. By unifying digital engagement, diagnostics, and national distribution under a single corporate umbrella, the platform aims to lower barriers to treatment for a severely underserved patient population.
